SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

Crescent Biopharma, Inc. backtest

10 trend-following strategies were compared on the full daily history of Crescent Biopharma, Inc.. 10 beat buy-and-hold CAGR; Supertrend ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is Keltner 채널 돌파 (CAGR 7.3%, MDD -44.4%).

Data 2014-01-10 ~ 2026-07-31daily bars 3,157 (12.6 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

10 of 10 beat buy and hold (CAGR -28.1%, drawdown -99.6%).

Sharpe leader (same as main): Supertrend — CAGR 14.6%, MDD -71.7%, Sharpe 0.46, 39% exposure.

Return/drawdown alternative: Keltner 채널 돌파 — CAGR is 42.7%p higher than buy and hold, while drawdown improves by 27.9%p (CAGR 7.3%, MDD -44.4%, exposure 4%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
Supertrend
period=11, mult=2.3
14.6%-71.7%0.460.205.5x9039%
MACD
fast=17, slow=51, signal=23
10.3%-75.5%0.430.143.4x10850%
볼린저 밴드 돌파
n=25, k=2.1
11.7%-67.2%0.420.174.0x8022%
SMA 크로스오버
fast=11, slow=39
9.9%-71.6%0.410.143.3x8642%
Keltner 채널 돌파
emaPeriod=19, atrPeriod=23, mult=4
7.3%-44.4%0.410.172.4x104%
EMA 크로스오버
fast=12, slow=28
8.8%-76.9%0.400.112.9x8440%
ADX / DI 방향성
period=33, threshold=15
10.3%-65.3%0.390.163.4x5621%
ROC 모멘텀
n=29, threshold=-0.04
4.7%-78.6%0.370.061.8x24650%
Donchian 채널 돌파
entryN=94, exitN=8
4.7%-62.7%0.340.081.8x189%
Parabolic SAR
step=0.01, maxStep=0.26
-4.6%-80.6%0.24-0.060.6x15843%
Buy and hold-28.1%-99.6%0.16-0.280.0x1100%
0.01 0.1 1x 10x 2015 2017 2019 2021 2023 2025 SupertrendBuy and hold
Supertrend: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -25% -50% -75% -100% 2015 2017 2019 2021 2023 2025 Buy and holdSupertrend
Supertrend maximum drawdown -71.7% (2024-10-29 → 2026-03-19), prior peak not yet recovered.

Rules of the top strategy

Trades the direction of a volatility-based trend line that trails below/above price.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next